Oncology Institute, Inc. Cash Flow Statement
TOI|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Oncology Institute, Inc. used $27M in operating cash flow and negative free cash flow of $30M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$64.7M | -$83.1M | $152.0K | -$10.9M | -$14.3M |
| Depreciation & Amortization | $6.3M | $5.9M | $4.4M | $3.3M | $3.2M |
| Operating Cash Flow | -$26.5M | -$36.3M | -$61.8M | -$32.7M | $508.0K |
| Capital Expenditures | $3.8M | $4.6M | $5.5M | $2.8M | $1.2M |
| Free Cash Flow | -$30.3M | -$40.9M | -$67.3M | -$35.5M | -$686.0K |
| Share Buybacks | - | $1.0M | $9.0M | $0 | - |
| FCF Margin | -7.7% | -12.6% | -26.7% | -17.5% | -0.4% |